Effects of ferric citrate in patients with nondialysis-dependent CKD and iron deficiency anemia

Journal of the American Society of Nephrology

Volumn 28, Issue 6, 2017, Pages 1851-1858

  Fishbane, Steven ^a   Block, Geoffrey A ^b   Loram, Lisa ^c   Neylan, John ^c   Pergola, Pablo E ^d   Uhlig, Katrin ^c   Chertow, Glenn M ^e  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^b Denver Nephrology   (United States)

^c AKEBIA THERAPEUTICS   (United States)

^d Renal Assocs   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICARBONATE; CITRIC ACID; FERRIC CITRATE; FERRITIN; FIBROBLAST GROWTH FACTOR 23; HEMOGLOBIN; PARATHYROID HORMONE; PHOSPHATE; PHOSPHORUS; PLACEBO; SERUM ALBUMIN; TRANSFERRIN; FERRIC ION;

ABDOMINAL PAIN; ADULT; ADVERSE OUTCOME; AGED; ALUMINUM BLOOD LEVEL; ARTICLE; BICARBONATE BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FECES COLOR; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; HYPERKALEMIA; HYPERTENSION; IRON DEFICIENCY ANEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TIME TO TREATMENT; TREATMENT RESPONSE; ANEMIA, IRON-DEFICIENCY; COMPLICATION; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA, IRON-DEFICIENCY; DOUBLE-BLIND METHOD; FEMALE; FERRIC COMPOUNDS; HUMANS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC;

EID: 85018007128     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2016101053     Document Type: Article

References (30)

1. Stauffer ME, Fan T: Prevalence of anemia in chronic kidney disease in the United States. PLoS One 9: E84943, 2014.
2. Stancu S, Stanciu A, Zugravu A, Bârsan L, Dumitru D, Lipan M, Mircescu G: Bone marrow iron, iron indices, and the response to intravenous iron in patientswith non-dialysis-dependent CKD. Am J Kidney Dis 55: 639- 647, 2010.
3. Rao M, Pereira BJ: Optimal anemia management reduces cardiovascular morbidity, mortality, and costs in chronic kidney disease. Kidney Int 68: 1432-1438, 2005.
4. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R; TREAT Investigators: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361: 2019-2032, 2009.
5. Kidney Disease Improving Global Outcomes (KDIGO) Anemia Work Group: KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2: 279-335, 2012.
6. Wood MM, Elwood PC: Symptoms of iron deficiency anaemia. A community survey. Br J Prev Soc Med 20: 117-121, 1966.
7. Fishbane S, Pollack S, Feldman HI, Joffe MM: Iron indices in chronic kidney disease in the national health and nutritional examination survey 1988-2004. Clin J Am Soc Nephrol 4: 57-61, 2009.
8. Gotloib L, Silverberg D, Fudin R, Shostak A: Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J Nephrol 19: 161-167, 2006.
9. Macdougall IC: Iron treatment strategies in nondialysis CKD. Semin Nephrol 36: 99-104, 2016.
10. Wetmore JB, Peng Y, Jackson S, Matlon TJ, Collins AJ, Gilbertson DT: Patient characteristics, disease burden, and medication use in stage 4 - 5 chronic kidney disease patients. Clin Nephrol 85: 101-111, 2016.
11. Macdougall IC, Bircher AJ, Eckardt KU, Obrador GT, Pollock CA, Stenvinkel P, Swinkels DW, Wanner C, Weiss G, Chertow GM; Conference Participants: Iron management in chronic kidney disease: Conclusions from a "kidney disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int 89: 28-39, 2016.
12. Wang C, Graham DJ, Kane RC, Xie D, Wernecke M, Levenson M, MaCurdy TE, Houstoun M, Ryan Q, Wong S, Mott K, Sheu TC, Limb S, Worrall C, Kelman JA, Reichman ME: Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA 314: 2062- 2068, 2015.
13. Lewis JB, SikaM, Koury MJ, Chuang P, Schulman G, Smith MT, Whittier FC, Linfert DR, Galphin CM, Athreya BP, Nossuli AK, Chang IJ, Blumenthal SS, Manley J, Zeig S, Kant KS, Olivero JJ, Greene T, Dwyer JP; Collaborative Study Group: Ferric citrate controls phosphorus and delivers iron in patients on dialysis. J Am Soc Nephrol 26: 493-503, 2015.
14. Available at: http://www.centerwatch.com/drug-information/fdaapproved-drugs/drug/100033/auryxia-ferric-citrate. Accessed June 2, 2016.
15. Umanath K, Jalal DI, Greco BA, Umeukeje EM, Reisin E, Manley J, Zeig S, Negoi DG, Hiremath AN, Blumenthal SS, Sika M, Niecestro R, Koury MJ, Ma KN, Greene T, Lewis JB, Dwyer JP; Collaborative Study Group: Ferric citrate reduces intravenous iron and erythropoiesis-stimulating agent use in ESRD. J AmSoc Nephrol 26: 2578-2587, 2015.
16. Block GA, Fishbane S, Rodriguez M, Smits G, Shemesh S, Pergola PE, Wolf M, Chertow GM: A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5. Am J Kidney Dis 65: 728-736, 2015.
17. Kalra PA, Bhandari S, Saxena S, Agarwal D, Wirtz G, Kletzmayr J, Thomsen LL, Coyne DW: A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia. Nephrol Dial Transplant 31: 646-655, 2016.
18. Macdougall IC, Bock AH, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, Roubert B, Nolen JG, Roger SD; FIND-CKD Study Investigators: FIND-CKD: A randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant 29: 2075-2084, 2014.
19. Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE: A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 50: 1694-1699, 1996.
20. Fudin R, Jaichenko J, Shostak A, Bennett M, Gotloib L: Correction of uremic iron deficiency anemia in hemodialyzed patients: A prospective study. Nephron 79: 299-305, 1998.
21. Markowitz GS, Kahn GA, Feingold RE, Coco M, Lynn RI: An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. Clin Nephrol 48: 34-40, 1997.
22. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease- Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 76[113]: S1- S130, 2009.
23. Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, Allison MA, Asplin J, Smits G, Hoofnagle AN, Kooienga L, Thadhani R, Mannstadt M, Wolf M, Chertow GM: Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 23: 1407-1415, 2012.
24. Rebholz CM, Grams ME, Coresh J, Selvin E, Inker LA, Levey AS, Kimmel PL, Vasan RS, Eckfeldt JH, Feldman HI, Hsu CY, Lutsey PL; Chronic Kidney Disease Biomarkers Consortium: Serum fibroblast growth factor- 23 is associated with incident kidney disease.J Am Soc Nephrol 26: 192-200, 2015.
25. Scialla JJ, Astor BC, Isakova T, Xie H, Appel LJ, Wolf M: Mineral metabolites and CKD progression in AfricanAmericans. J AmSoc Nephrol 24: 125-135, 2013.
26. Scialla JJ, Xie H, Rahman M, Anderson AH, Isakova T, Ojo A, Zhang X, Nessel L, Hamano T, Grunwald JE, Raj DS, Yang W, He J, Lash JP, Go AS, Kusek JW, Feldman H, Wolf M; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators: Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol 25: 349-360, 2014.
27. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutiérrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M; Chronic Renal Insufficiency Cohort (CRIC) Study Group: Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305: 2432-2439, 2011.
28. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutiérrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, John Sutton M, Ojo A, Gadegbeku C, DiMarco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro OM, Kusek JW, Keane MG, Wolf M: FGF23 induces left ventricular hypertrophy. J Clin Invest 121: 4393-4408, 2011.
29. Kobune M, Miyanishi K, Takada K, Kawano Y, Nagashima H, Kikuchi S, Murase K, Iyama S, Sato T, Sato Y, Takimoto R, Kato J: Establishment of a simple test for iron absorption from the gastrointestinal tract. Int J Hematol 93: 715-719, 2011.
30. Ganz T, Nemeth E: Iron balance and the role of hepcidin in chronic kidney disease. Semin Nephrol 36: 87-93, 2016.